The Metformin Active Surveillance Trial (MAST) Study

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 16, 2024

Study Completion Date

August 31, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Metformin

One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.

DRUG

Placebo

One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.

Trial Locations (12)

R3E 0V9

Manitoba Cancer Care Centre, Winnipeg

B2H 1Y6

CDHA - Victoria Site, Halifax

L8N 4A6

McMaster Institute of Urology-St .Joseph's Healthcare, Hamilton

K7L 3J7

Centre for Appled Urologic Research, Kingston General Hospital, Kingston

N6A 5W9

London Health Sciences Centre-Victoria Hospital, London

K1H 8L6

Ottawa Hospital Research Institute (The Ottawa Hospital), Ottawa

M4N 3M5

Sunnybrook Research Institute, Toronto

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H2L 4M1

Centre L'Hopitalie de l'Universite de Montreal, Montreal

Unknown

MUHC - Montreal General Hospital, Montreal

Alberta Urology Institute, Edmonton

J1J 3H5

Centre de Recherche du CHUS, Sherbrooke

All Listed Sponsors
lead

University Health Network, Toronto

OTHER